Whereas embelin significantly reduced the percentage of CD19+ B cells 7 days after infection, a timepoint at which most surviving B cells are EBV infected, it did not significantly reduce CD56+ NK, CD4+, or CD8+ T cell frequency (Figure 5, A and B). The gene discussed is CD19; the disease is infection.